0001193125-23-212358.txt : 20230814 0001193125-23-212358.hdr.sgml : 20230814 20230814161629 ACCESSION NUMBER: 0001193125-23-212358 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 14 CONFORMED PERIOD OF REPORT: 20230814 ITEM INFORMATION: Results of Operations and Financial Condition ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230814 DATE AS OF CHANGE: 20230814 FILER: COMPANY DATA: COMPANY CONFORMED NAME: Alaunos Therapeutics, Inc. CENTRAL INDEX KEY: 0001107421 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 841475642 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 001-33038 FILM NUMBER: 231170447 BUSINESS ADDRESS: STREET 1: 8030 EL RIO STREET CITY: HOUSTON STATE: TX ZIP: 77054 BUSINESS PHONE: (346) 355-4099 MAIL ADDRESS: STREET 1: 8030 EL RIO STREET CITY: HOUSTON STATE: TX ZIP: 77054 FORMER COMPANY: FORMER CONFORMED NAME: ZIOPHARM ONCOLOGY INC DATE OF NAME CHANGE: 20050919 FORMER COMPANY: FORMER CONFORMED NAME: EASYWEB INC DATE OF NAME CHANGE: 20010213 8-K 1 d467190d8k.htm 8-K 8-K
false 0001107421 0001107421 2023-08-14 2023-08-14

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 14, 2023

 

 

Alaunos Therapeutics, Inc.

(Exact name of registrant as specified in its charter)

 

 

 

Delaware   001-33038   84-1475642

(State or other jurisdiction

of incorporation)

  

(Commission

File Number)

  

(IRS Employer

Identification No.)

8030 El Rio Street

Houston, TX 77054

(Address of principal executive offices, including zip code)

(346) 355-4099

(Registrant’s telephone number, including area code)

Not applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

☐

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

☐

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

☐

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

☐

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class

  

Trading
Symbol(s)

  

Name of each exchange
on which registered

Common Stock, par value $0.001 per share   TCRT   The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

 

 

 

Item 2.02 Results of Operations and Financial Condition.

On August 14, 2023, Alaunos Therapeutics, Inc. (the “Company”) issued a press release announcing financial results for the three and six months ended June 30, 2023, interim clinical data and exploration of strategic alternatives. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information contained in this Item 2.02, including Exhibit 99.1, is being “furnished” and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liability of that Section or Sections 11 and 12(a)(2) of the Securities Act of 1933, as amended (the “Securities Act”). The information contained in this Item 2.02, including Exhibit 99.1, shall not be incorporated by reference into any registration statement or other document pursuant to the Securities Act or into any filing or other document pursuant to the Exchange Act, except as otherwise expressly stated in any such filing.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit No.

   

Description

99.1    Press Release of Alaunos Therapeutics, Inc., dated August 14, 2023.
104    Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

    Alaunos Therapeutics, Inc.
Date. August 14, 2023     By:  

/s/ Melinda Lackey

      Name: Melinda Lackey
      Title: Senior Vice President, Legal and Administration
 EX-99.1 2 d467190dex991.htm EX-99.1 EX-99.1

Exhibit 99.1

 

LOGO

Alaunos Therapeutics Announces Second Quarter 2023 Financial Results, Interim

Clinical Data and Exploration of Strategic Alternatives

 

  •  

TCR-T Library Phase 1/2 trial achieved an 83% disease control rate of six evaluable patients with metastatic, refractory solid tumors; TCR-T cell therapy was well tolerated in all evaluable patients

 

  •  

Company to wind down TCR-T Library Phase 1/2 trial and concurrently explore potential partnering opportunities for the hunTR® platform as well as broad strategic alternatives

 

  •  

Reducing headcount by approximately 60% while retaining key hunTR® R&D capabilities

HOUSTON, August 14, 2023 – Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced financial results for the second quarter ended June 30, 2023. The Company also announced a strategic reprioritization to focus on its hunTR® TCR discovery platform, wind down its TCR-T Phase 1/2 Library trial and explore broad strategic alternatives for the Company. Alaunos is implementing a cost-savings plan that includes a reduction in workforce by approximately 60%.

“Over the past two years, we have advanced the medical field’s understanding of TCR-T cell therapies using our innovative Sleeping Beauty technology targeting high-frequency driver mutations,” said Kevin S. Boyle, Sr., Chief Executive Officer of Alaunos. “We continue to believe that this approach has potential in targeting the heart of cancer growth. However, after a review of the funding needs of our TCR-T Library Phase 1/2 trial and the current financial markets, the Board of Directors has made the difficult decision to limit further drug development under our clinical trial and to focus on our promising hunTR® TCR discovery platform as we explore all strategic alternatives.”

Operational & Corporate Update

Interim Clinical Data from TCR-T Library Phase 1/2 Trial: Eight patients have been treated in the Company’s TCR-T Library Phase 1/2 trial to date, six of which are evaluable as of today. The trial showed that the Company’s T-cells were generally well-tolerated in all evaluable participants and achieved an 83% disease control rate in evaluable patients with metastatic, refractory solid tumors. Disease control is measured by objective responses and stable disease. Persistence of TCR-T cells in peripheral blood was detected in all evaluable patients at last follow-up.

hunTR® TCR Discovery Platform Identifies Proprietary TCRs: Alaunos has discovered multiple proprietary TCRs targeting driver mutations through its hunTR® TCR discovery platform. The hunTR® platform can rapidly interrogate T-cell responses and has the potential to expand to multiple targets or cancer indications. Using hunTR®, the Company has demonstrated the ability to isolate neoantigen specific TCRs from tumor resident T-cells. The presence of these driver mutation specific T-cells in the tumor potentially validates the relevance of the mutated target and safety of the TCR for use in other cancer patients expressing the same neoantigen.

Restructuring Organization and Winding Down TCR-T Library Phase 1/2 Trial: Alaunos has decided to wind down its TCR-T Library Phase 1/2 trial and prioritize the hunTR® platform to explore potential partnering opportunities. Concurrently, the Company is exploring strategic alternatives and has engaged Cantor Fitzgerald & Co. to act as a strategic advisor for this process. Strategic options may include but are not limited to, an acquisition, merger, reverse merger, sale of assets, strategic partnerships, capital raises or other transactions. The Company will reduce its workforce by approximately 60% to streamline the organization, while retaining key R&D capabilities for the hunTR® platform and to assist in the strategic alternatives review process. Alaunos does not intend to comment further on this process unless or until its Board of Directors has approved a definitive course of action or it is determined that other disclosure is appropriate.

Second Quarter Ended June 30, 2023, Financial Results

Research and Development Expenses: Research and development expenses were $5.2 million for the second quarter of 2023, compared to $5.9 million for the second quarter of 2022, a decrease of approximately 13%. The decrease was primarily due to an accrual adjustment related to one of our de-prioritized clinical programs of $0.7 million.

General and Administrative Expenses: General and administrative expenses were $3.0 million for the second quarter of 2023, compared to $3.4 million for the second quarter of 2022, a decrease of approximately 11%. The decrease was primarily due to lower employee-related expenses of $0.1 million due to our reduced headcount, a $0.1 million decrease in consulting and professional services related to lower legal fees and the reduced use of consultants, and a $0.2 million decrease in insurance fees.

Net Loss: Net loss was $8.8 million, or $(0.04) per share, for the second quarter of 2023, compared to a net loss of $9.9 million, or $(0.05) per share, for the second quarter in 2022.

Cash, Cash Equivalents and Restricted Cash: As of June 30, 2023, Alaunos had approximately $18.3 million in cash balances. The Company expects to have sufficient cash resources to fund operations into the fourth quarter of 2023, after implementing the strategic reprioritization laid out above.

About Alaunos Therapeutics, Inc.

Alaunos Therapeutics is a T-cell receptor (TCR) cell therapy company powered by its hunTR® (human neoantigen T-cell Receptor) discovery platform. hunTR® enables the rapid identification of wholly owned, proprietary TCRs. Using a proprietary high-throughput TCR screening process, hunTR® enables rapid functional validation of TCRs potentially allowing Alaunos to advance new TCRs from the lab to testing in the clinic. For more information, visit www.alaunos.com.

Forward-Looking Statements Disclaimer

This press release contains forward-looking statements as defined in the Private Securities Litigation Reform Act of 1995, as amended. Forward-looking statements are statements that are not historical facts, and in some cases can be identified by terms such as “may,” “will,” “could,” “expects,” “plans,” “anticipates,” “believes” or other words or terms of similar meaning. These statements include, but are not limited to, statements regarding the Company evaluating strategic alternatives and the potential outcomes; the completion and impact of the reduction in workforce; the planned renewed focus on the hunTR® TCR discovery platform and its success, including its ability to discover additional TCRs and the ability to monetize any newly discovered TCRs; the wind down of the TCR-T Phase 1/2 Library trial; and the results and potential of the TCR-T Phase 1/2 Library trial. Although the management team of Alaunos believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks and uncertainties, many of which are difficult to predict and generally beyond the control of Alaunos, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. These risks and uncertainties include, among other things, risks relating to volatility and uncertainty in the capital markets for biotechnology and cell therapy companies; availability of suitable third parties with which to conduct contemplated strategic transactions; whether the Company will be able to pursue a strategic transaction, or whether any transaction, if pursued, will be completed successfully and on attractive terms or at all; whether our cash resources will be sufficient to fund the Company’s foreseeable and unforeseeable operating expenses and capital requirements; changes in the Company’s operating plans that may impact its cash expenditures; the uncertainties inherent in research and development, future clinical data and analysis; the risks associated with reductions in workforce, including reduced morale and attrition of additional employees necessary for the strategic reprioritization; the Company’s exclusive focus on its hunTR® TCR discovery platform; the strength and enforceability of Alaunos’ intellectual property rights; competition from other pharmaceutical and biotechnology companies; the impacts related to or resulting from recent bank failures and other economic and industry volatility; and the potential delisting of the Company’s common stock from the Nasdaq Stock Market LLC, as well as risk factors discussed or identified in the public filings with the Securities and Exchange Commission made by Alaunos, including those risks and uncertainties listed in the most recent periodic report filed by Alaunos with the Securities and Exchange Commission. Alaunos is providing this information as of the date of this press release, and Alaunos does not undertake any obligation to update or revise the information contained in this press release whether as a result of new information, future events, or any other reason.

Investor Relations Contact:

Alex Lobo

Stern Investor Relations

Alex.lobo@sternir.com

Media Contact:

Heather Anderson

6 Degrees PR

handerson@6degreespr.com

Alaunos Therapeutics, Inc.

Statement of Operations

(In thousands except per share data)

 

     For the Three Months Ended
June 30
(Unaudited)		  
     2023     2022  

Collaboration revenue

    $ 4     $ —    

Operating expenses:

     

Research and development

    $ 5,186     $ 5,937  

General and administrative

      3,045       3,429  

Gain on lease modification

      (245 )      (133 ) 
  

 

 

    

 

 

  

Total operating expenses

      7,986       9,233  
  

 

 

    

 

 

  

Loss from operations

      (7,982 )      (9,233 ) 

Interest expense

      (1,068 )      (740 ) 

Other income, net

      277       41  

Net loss

      (8,773 )      (9,932 ) 

Basic and diluted net loss per share

    $ (0.04 )    $ (0.05 ) 
  

 

 

    

 

 

  

Weighted average common shares outstanding, basic and diluted

      239,797,574       214,998,893  
  

 

 

    

 

 

  

Alaunos Therapeutics, Inc.

Selected Balance Sheet Data

(In thousands)

 

     June 30,
2023
(Unaudited)		      December 31,
2022
(Audited)		  

Cash and cash equivalents

    $ 18,317      $ 39,058  

Restricted cash

    $ —        $ 13,938  

Working capital, excluding restricted cash

    $ 13,726      $ 15,695  
  

 

 

     

 

 

  

Total assets

    $ 27,927      $ 64,937  
  

 

 

     

 

 

  

Total stockholders’ equity

    $ 21,650      $ 38,555  
  

 

 

     

 

 

  
 EX-101.SCH 3 tcrt-20230814.xsd XBRL TAXONOMY EXTENSION SCHEMA 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink EX-101.LAB 4 tcrt-20230814_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Cover [Abstract] Cover [Abstract] Amendment Flag Amendment Flag Entity Central Index Key Entity Central Index Key Document Type Document Type Document Period End Date Document Period End Date Entity Registrant Name Entity Registrant Name Entity Incorporation State Country Code Entity Incorporation State Country Code Entity File Number Entity File Number Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Entity Address, City or Town Entity Address, City or Town Entity Address, State or Province Entity Address, State or Province Entity Address, Postal Zip Code Entity Address, Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Written Communications Written Communications Soliciting Material Soliciting Material Pre Commencement Tender Offer Pre Commencement Tender Offer Pre Commencement Issuer Tender Offer Pre Commencement Issuer Tender Offer Security 12b Title Security 12b Title Trading Symbol Trading Symbol Security Exchange Name Security Exchange Name Entity Emerging Growth Company Entity Emerging Growth Company EX-101.PRE 5 tcrt-20230814_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE GRAPHIC 6 g467190g0814174756026.jpg GRAPHIC begin 644 g467190g0814174756026.jpg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end XML 7 R1.htm IDEA: XBRL DOCUMENT v3.23.2
Document and Entity Information
Aug. 14, 2023
Cover [Abstract]  
Amendment Flag false
Entity Central Index Key 0001107421
Document Type 8-K
Document Period End Date Aug. 14, 2023
Entity Registrant Name Alaunos Therapeutics, Inc.
Entity Incorporation State Country Code DE
Entity File Number 001-33038
Entity Tax Identification Number 84-1475642
Entity Address, Address Line One 8030 El Rio Street
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77054
City Area Code (346)
Local Phone Number 355-4099
Written Communications false
Soliciting Material false
Pre Commencement Tender Offer false
Pre Commencement Issuer Tender Offer false
Security 12b Title Common Stock, par value $0.001 per share
Trading Symbol TCRT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
XML 8 d467190d8k_htm.xml IDEA: XBRL DOCUMENT 0001107421 2023-08-14 2023-08-14 false 0001107421 8-K 2023-08-14 Alaunos Therapeutics, Inc. DE 001-33038 84-1475642 8030 El Rio Street Houston TX 77054 (346) 355-4099 false false false false Common Stock, par value $0.001 per share TCRT NASDAQ false EXCEL 9 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 10 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 11 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 12 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.2 html 1 22 1 false 0 0 false 0 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false All Reports Book All Reports d467190d8k.htm d467190dex991.htm tcrt-20230814.xsd tcrt-20230814_lab.xml tcrt-20230814_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 14 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "d467190d8k.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 22 }, "contextCount": 1, "dts": { "inline": { "local": [ "d467190d8k.htm" ] }, "labelLink": { "local": [ "tcrt-20230814_lab.xml" ] }, "presentationLink": { "local": [ "tcrt-20230814_pre.xml" ] }, "schema": { "local": [ "tcrt-20230814.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/dtr/type/nonNumeric-2009-12-16.xsd", "http://www.xbrl.org/dtr/type/numeric-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd", "https://xbrl.sec.gov/naics/2022/naics-2022.xsd" ] } }, "elementCount": 23, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 2, "total": 2 }, "keyCustom": 0, "keyStandard": 22, "memberCustom": 0, "memberStandard": 0, "nsprefix": "tcrt", "nsuri": "http://alaunos.com/20230814", "report": { "R1": { "firstAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d467190d8k.htm", "contextRef": "duration_2023-08-14_to_2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "100000 - Document - Document and Entity Information", "menuCat": "Cover", "order": "1", "role": "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation", "shortName": "Document and Entity Information", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "p", "div", "div", "body", "html" ], "baseRef": "d467190d8k.htm", "contextRef": "duration_2023-08-14_to_2023-08-14", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation State Country Code", "terseLabel": "Entity Incorporation State Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre Commencement Issuer Tender Offer", "terseLabel": "Pre Commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre Commencement Tender Offer", "terseLabel": "Pre Commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Security 12b Title", "terseLabel": "Security 12b Title" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://alaunos.com//20230814/taxonomy/role/DocumentDocumentAndEntityInformation" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 15 0001193125-23-212358-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001193125-23-212358-xbrl.zip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end